Corixa Corporation (Corixa) is a product development company engaged in
developing immunology-based products that regulate innate immune
responses. The Company's products include vaccine adjuvants, and
toll-like receptor 4 (TLR4) agonists and antagonists. Vaccine adjuvants
are compounds or additives that, when combined with a vaccine, boost
the body's immune response to antigens contained in the vaccine. TLR4
agonists and antagonists are compound...
more
Corixa Corporation (Corixa) is a product development company engaged in
developing immunology-based products that regulate innate immune
responses. The Company's products include vaccine adjuvants, and
toll-like receptor 4 (TLR4) agonists and antagonists. Vaccine adjuvants
are compounds or additives that, when combined with a vaccine, boost
the body's immune response to antigens contained in the vaccine. TLR4
agonists and antagonists are compounds that interact with a type of
cell surface receptor that recognizes distinct molecular signatures
presented by invading pathogens and generates an immune response. These
multiple product candidates are in late-stage human clinical trials.
Corixa sells products to and records collaborative revenue from a
limited number of pharmaceutical and biotechnology companies.
Corixa
was a biotechnology/pharmaceutical company based in Seattle, Washington
involved in the development of immunotherapeutics to combat autoimmune
diseases, infectious diseases, and cancer. It was founded in 1994. It
operates a laboratory and production facility in Hamilton, Montana.
less
